Alembic Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, Alembic Pharmaceuticals (APLLTD) reported revenue ₹1,874 Cr and net profit ₹202 Cr — revenue +5.0% YoY. Compare with APLLTD fundamental valuation to assess whether the stock is under or overvalued.
APLLTD Quarterly Results — Revenue, Profit & EPS Highlights
Alembic Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore APLLTD share price data to track price trends across different timeframes.
- Revenue of ₹1,874 Cr in Mar 2026 (-2.3% vs Sept 2025, +5.0% vs Mar 2025)
- Net Profit of ₹202 Cr in Mar 2026 (+9.8% vs Sept 2025, +28.7% vs Mar 2025)
- EBITDA of ₹230 Cr in Mar 2026 (-29.0% vs Sept 2025)
- Operating Margin of 11.0% in Mar 2026 (-6.0pp vs Sept 2025)
- Earnings Per Share of ₹10.31 in Mar 2026 (+9.7% vs Sept 2025)
Alembic Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
APLLTD quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 1,874 | 1,919 | 1,784 | 1,717 | 1,892 | -2.3% | 5.0% |
| Net Profit (₹ Cr) | 202 | 184 | 157 | 154 | 132 | - | - |
| EBITDA (₹ Cr) | 230 | 324 | 286 | 287 | 265 | - | - |
| EPS (₹) | 10.31 | 9.40 | 7.98 | 7.85 | 6.76 | - | - |
| Operating Margin (%) | 11.0% | 17.0% | 15.0% | 16.0% | 13.0% | - | - |
APLLTD Share Price Trend — 1-Year Movement Across Quarterly Results
Alembic Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Alembic Pharmaceuticals screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
APLLTD vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Alembic Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹441,069.70 Cr | 1862.8 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 164.8 |
|
Divis Laboratories
Mar 2026 |
₹180,186.80 Cr | 6713.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 237.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹152,449.36 Cr | 4516.2 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 392.4 |
|
Cipla
Mar 2026 |
₹116,150.78 Cr | 1440.1 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 209.6 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,873.98 Cr | 1350.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 509.6 |
All amounts in ₹ Crores